[Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003666
German
Original Title:
Elotuzumab (multiples Myelom) - Addendum zum Auftrag A19-80
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a20-12.html
Year Published:
2020
URL for published report:
https://www.iqwig.de/download/A20-12_Elotuzumab_Addendum-zum-Auftrag-A19-80_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Multiple Myeloma
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
Keywords
- Elotuzumab
- Pomalidomide
- Dexamethasone
- Multiple Myeloma
- Benefit Assessment
- NCT02654132
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.